data_2rlj_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2rlj _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 60.78 30.56 19.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.831 0.348 . . . . 0.0 111.073 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.4 -70.01 0.81 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.046 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.4 tp -142.91 -42.27 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.013 0.435 . . . . 0.0 111.253 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -53.9 -23.48 23.1 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.545 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 55.3 tp -120.77 62.84 0.87 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.998 0.428 . . . . 0.0 110.694 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -120.91 44.11 2.59 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.286 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.402 ' C ' ' HD2' ' A' ' 10' ' ' PRO . 46.3 p-90 -125.29 -34.59 2.7 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.44 0.638 . . . . 0.0 110.235 179.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.758 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.5 tt -62.97 -36.05 22.55 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.123 -0.944 . . . . 0.0 113.041 -179.015 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.758 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.2 Cg_endo -39.99 -27.53 0.22 Allowed 'Trans proline' 0 C--N 1.358 1.073 0 C-N-CA 122.316 2.011 . . . . 0.0 112.531 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.57 -37.74 82.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.582 179.015 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -84.28 -30.76 25.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.577 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 137.38 121.79 2.05 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.361 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -50.79 -39.8 57.44 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.51 2.14 . . . . 0.0 112.319 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -102.93 55.42 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.961 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.027 -179.811 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.87 -33.63 34.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.776 0.322 . . . . 0.0 111.069 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.54 69.0 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.1 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.4 pt -82.28 0.97 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.613 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 123.43 -18.48 7.74 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.412 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.444 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 3.7 mp -126.33 42.09 3.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.805 0.335 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.25 19.78 17.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.434 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 36.6 p-90 -112.44 -38.32 4.7 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.073 0.463 . . . . 0.0 110.6 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.687 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -54.1 -42.79 95.33 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.606 -179.052 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.687 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.1 Cg_endo -41.96 -28.45 0.79 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.29 1.993 . . . . 0.0 111.714 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.6 m-30 -54.84 -39.1 68.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.877 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -81.49 -30.17 33.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.971 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 151.36 109.51 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.533 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -68.8 -27.57 31.2 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.444 2.096 . . . . 0.0 112.324 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.89 -20.72 25.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.332 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.216 -0.897 . . . . 0.0 111.132 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 61.77 64.34 1.04 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.948 0.404 . . . . 0.0 111.001 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -172.21 -78.15 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.077 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 59.2 mt -114.29 -19.03 7.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.273 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 121.29 -16.84 9.14 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.532 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.493 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 43.7 tp -151.54 31.38 0.58 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.998 0.428 . . . . 0.0 110.425 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.71 40.9 1.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.9 p-90 -126.72 -34.21 2.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.276 0.56 . . . . 0.0 110.419 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.744 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -62.07 -37.65 40.37 Favored Pre-proline 0 N--CA 1.451 -0.395 0 CA-C-N 115.254 -0.884 . . . . 0.0 112.987 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.744 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.3 Cg_endo -41.78 -26.19 0.41 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.215 1.943 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.07 -38.02 81.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -75.99 -27.63 57.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -135.06 72.99 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.551 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.62 -71.92 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.672 2.248 . . . . 0.0 112.27 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.77 97.12 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.115 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.05 179.979 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.209 0 N-CA-C 112.396 -0.281 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.75 -43.32 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.785 0.326 . . . . 0.0 111.162 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.06 51.96 6.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.027 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.446 HD11 HG23 ' A' ' 4' ' ' ILE . 52.6 mt -110.73 -17.74 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.137 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 94.08 3.78 63.46 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.391 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.502 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 44.2 tp -159.07 29.15 0.21 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.038 0.446 . . . . 0.0 110.516 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -92.73 22.12 5.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.438 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.461 ' CZ3' ' CZ ' ' A' ' 12' ' ' PHE . 23.9 p-90 -107.03 -38.37 6.05 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.629 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.711 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -55.44 -42.36 95.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.792 179.641 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.711 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.3 Cg_endo -43.07 -29.63 1.69 Allowed 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 121.849 1.699 . . . . 0.0 110.678 178.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.409 ' CG ' ' O ' ' A' ' 8' ' ' TRP . 8.8 m-30 -56.21 -54.3 46.9 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.539 178.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.552 ' CE1' HG12 ' A' ' 9' ' ' ILE . 6.4 p90 -106.16 20.56 18.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.985 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.413 ' HA3' HD13 ' A' ' 9' ' ' ILE . . . -167.84 73.66 0.14 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.576 179.453 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.04 -62.39 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.631 2.221 . . . . 0.0 112.227 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.73 70.81 2.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.973 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.281 -0.866 . . . . 0.0 111.061 179.936 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 112.579 -0.209 . . . . 0.0 112.579 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.14 30.14 0.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 111.203 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -67.87 -44.77 76.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 49.8 mm -118.69 -7.64 11.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.207 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.75 -15.97 55.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.384 -0.912 . . . . 0.0 111.583 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.429 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 3.9 mp -129.73 24.08 5.39 Favored 'General case' 0 N--CA 1.458 -0.069 0 CA-C-O 120.737 0.303 . . . . 0.0 110.897 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -116.58 60.73 0.73 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.014 0.435 . . . . 0.0 111.1 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 39.7 p-90 -129.34 -36.07 1.72 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.476 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.732 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.8 tt -58.99 -38.81 68.68 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.815 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.732 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -40.85 -29.4 0.44 Allowed 'Trans proline' 0 C--N 1.357 1.008 0 C-N-CA 122.243 1.962 . . . . 0.0 111.84 179.731 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 9.1 m-30 -53.84 -44.84 70.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.699 178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -79.46 -0.59 33.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.642 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.25 57.46 0.48 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.539 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.3 107.49 1.78 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.524 2.15 . . . . 0.0 112.305 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -131.64 -81.86 0.51 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.172 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.226 -0.892 . . . . 0.0 111.187 179.991 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.161 0 N-CA-C 112.519 -0.233 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -167.98 -43.13 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.828 0.347 . . . . 0.0 111.097 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.5 64.46 1.33 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.124 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 57.2 mt -112.98 -17.44 8.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.84 -12.23 32.25 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.408 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 88.3 mt -135.91 16.78 3.28 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.692 0.282 . . . . 0.0 111.236 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.16 36.05 2.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.976 0.417 . . . . 0.0 111.065 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.4 p-90 -126.88 -34.57 2.36 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.267 0.556 . . . . 0.0 110.403 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.748 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -61.9 -37.43 39.17 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.021 -178.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.748 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.3 Cg_endo -41.48 -26.41 0.37 Allowed 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 122.358 2.039 . . . . 0.0 112.214 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -60.21 -38.18 82.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.75 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -76.45 -27.83 56.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.796 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.17 90.12 0.53 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.439 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 173.21 11.33 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.632 2.222 . . . . 0.0 112.288 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -109.72 136.95 48.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.143 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.097 -180.0 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 112.438 -0.265 . . . . 0.0 112.438 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.1 25.48 13.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.818 0.342 . . . . 0.0 111.291 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -177.46 37.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.406 HG13 HD12 ' A' ' 6' ' ' LEU . 29.6 pt -85.14 6.51 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.913 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.25 -13.24 55.22 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.748 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.453 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 4.5 mp -106.2 61.37 0.65 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.971 0.415 . . . . 0.0 111.091 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -103.12 26.91 7.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.012 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.402 ' C ' ' HD2' ' A' ' 10' ' ' PRO . 40.8 p-90 -129.47 -37.78 1.58 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.318 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.708 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.6 tt -54.14 -39.88 77.67 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.691 -179.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.708 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.1 Cg_endo -42.08 -29.07 0.96 Allowed 'Trans proline' 0 C--N 1.355 0.907 0 C-N-CA 122.26 1.973 . . . . 0.0 111.908 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -48.21 -45.69 34.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.707 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 50.0 m-85 -75.2 -28.18 59.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.858 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.17 -114.63 0.03 OUTLIER Glycine 0 CA--C 1.519 0.294 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.548 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.66 -63.38 0.11 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.491 2.128 . . . . 0.0 112.34 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.91 74.7 0.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.09 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.992 -179.958 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -127.67 34.87 4.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.738 0.304 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.73 35.51 1.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.045 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.8 tt -103.85 -20.39 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.278 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.95 12.44 25.88 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.7 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 4.1 mp 46.82 29.73 1.06 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 111.31 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.76 39.54 2.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.118 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.4 p-90 -112.54 -35.35 5.56 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.647 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.75 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -64.91 -38.87 33.08 Favored Pre-proline 0 C--N 1.324 -0.503 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.145 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.75 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.7 -30.25 1.01 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 122.35 2.034 . . . . 0.0 111.536 179.811 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -64.01 -52.84 57.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.553 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -65.22 -15.18 62.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.13 105.97 3.05 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.626 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.52 154.11 12.51 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.395 2.063 . . . . 0.0 112.287 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -105.6 -178.45 3.65 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.143 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.36 -0.829 . . . . 0.0 111.039 179.987 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 61.25 29.94 18.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 111.157 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -176.15 -71.68 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.032 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 11.3 tt -116.33 -14.89 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.225 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.95 -10.39 62.09 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.248 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.442 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 3.7 mp -126.28 15.25 7.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.693 0.282 . . . . 0.0 111.063 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -95.0 41.34 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.99 0.424 . . . . 0.0 111.291 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 51.1 p-90 -125.32 -35.05 2.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.251 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.735 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 7.1 tt -58.51 -38.45 65.65 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 115.153 -0.93 . . . . 0.0 112.865 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.735 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.1 Cg_endo -40.04 -29.66 0.35 Allowed 'Trans proline' 0 C--N 1.357 1.0 0 C-N-CA 122.329 2.019 . . . . 0.0 112.11 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -52.44 -36.3 54.22 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.713 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -81.9 -34.11 30.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.729 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.44 78.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.634 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.23 158.59 55.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.62 2.214 . . . . 0.0 112.296 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -109.54 145.37 36.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.134 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.24 -42.85 2.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.704 0.287 . . . . 0.0 111.144 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.21 -84.05 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.115 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 11.6 tt -126.93 -17.82 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.731 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.29 -10.67 36.5 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.571 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.501 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 44.5 tp -155.13 29.74 0.4 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.086 0.47 . . . . 0.0 110.542 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -97.39 43.94 1.06 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.139 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 36.7 p-90 -126.81 -32.78 2.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.789 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 5.5 tt -69.1 -33.02 3.71 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.789 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.7 Cg_endo -39.48 -31.74 0.4 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.477 2.118 . . . . 0.0 112.188 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 -62.19 -48.69 78.93 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.438 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.409 ' N ' ' O ' ' A' ' 9' ' ' ILE . 8.4 m-30 -59.32 -19.58 47.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.619 179.078 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.08 -73.64 0.38 Allowed Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.644 -179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -68.1 -24.06 39.14 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.475 2.117 . . . . 0.0 112.381 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.68 50.99 1.9 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.131 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.288 -0.863 . . . . 0.0 111.12 -179.975 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 60.43 32.59 20.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.847 0.356 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.49 -57.35 4.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.1 tp -113.63 -17.13 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.236 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.24 -17.99 11.33 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.362 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 89.0 mt -144.74 24.01 1.54 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.704 0.288 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -107.37 33.36 4.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.993 0.425 . . . . 0.0 111.067 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.405 ' O ' ' CG ' ' A' ' 11' ' ' TYR . 42.0 p-90 -109.8 -37.6 5.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.399 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.695 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -53.43 -42.97 94.45 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.54 -0.755 . . . . 0.0 112.276 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.695 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -42.47 -28.13 0.93 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.233 1.955 . . . . 0.0 111.721 179.451 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.405 ' CG ' ' O ' ' A' ' 8' ' ' TRP . 8.7 m-30 -52.9 -36.73 59.77 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.838 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -70.31 -37.03 74.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.901 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 56.93 103.0 0.01 OUTLIER Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.563 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.67 126.23 13.76 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.516 2.144 . . . . 0.0 112.279 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -102.16 102.48 12.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.024 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.229 -0.891 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.199 0 N-CA-C 112.576 -0.209 . . . . 0.0 112.576 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.46 45.82 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.906 0.384 . . . . 0.0 111.016 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.76 -14.61 13.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.41 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.0 tp -119.74 -36.44 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.001 0.429 . . . . 0.0 111.099 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -60.3 -22.17 58.09 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.229 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.444 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 3.7 mp -126.11 31.04 5.51 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.791 0.329 . . . . 0.0 110.766 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.42 14.95 30.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.591 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 35.2 p-90 -111.3 -39.35 4.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.155 0.502 . . . . 0.0 110.61 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.692 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -53.62 -42.72 93.67 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.444 -179.18 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.692 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.9 -28.5 0.77 Allowed 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.26 1.973 . . . . 0.0 111.781 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -54.88 -39.18 68.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.89 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -79.5 -32.67 42.44 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.124 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.76 99.88 2.03 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.575 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -64.02 91.99 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.525 2.15 . . . . 0.0 112.19 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -146.32 74.32 1.36 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.116 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.114 179.997 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.134 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.74 35.98 4.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 111.12 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.65 -45.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.134 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 11.0 tt -117.61 -14.6 9.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.186 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.82 -3.22 87.17 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.129 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.416 ' CD2' ' N ' ' A' ' 6' ' ' LEU . 2.3 mm? -130.53 27.31 5.01 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.849 0.357 . . . . 0.0 110.734 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -92.65 48.72 1.39 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.713 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 39.9 p-90 -118.81 -37.31 3.27 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.812 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.739 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.7 tt -58.09 -38.91 71.55 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.652 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.739 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.0 -29.82 0.52 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.369 2.046 . . . . 0.0 111.763 179.428 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.6 m-30 -51.14 -45.42 61.63 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.475 178.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -83.02 -31.19 27.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.95 94.57 0.11 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.438 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.87 132.73 51.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.545 2.163 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.56 -176.9 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.207 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.149 -0.929 . . . . 0.0 111.072 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.168 0 N-CA-C 112.61 -0.196 . . . . 0.0 112.61 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.21 -30.59 20.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.854 0.359 . . . . 0.0 111.175 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.55 -76.7 0.58 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.982 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.9 tt -110.55 -20.28 6.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.96 -15.77 4.01 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.702 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 90.9 mt 52.29 33.93 13.71 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.815 0.341 . . . . 0.0 111.112 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -98.95 30.63 3.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.013 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.406 ' C ' ' HD2' ' A' ' 10' ' ' PRO . 52.7 p-90 -124.95 -36.55 2.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.32 0.581 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.716 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 7.3 tt -56.33 -38.98 74.32 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.886 -179.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.716 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.2 Cg_endo -40.15 -29.1 0.31 Allowed 'Trans proline' 0 C--N 1.358 1.029 0 C-N-CA 122.331 2.021 . . . . 0.0 112.112 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.1 m-30 -51.92 -33.01 35.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.747 179.183 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.431 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 4.4 m-85 -92.41 -34.29 14.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.275 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.32 104.86 0.53 Allowed Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.673 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 12' ' ' PHE . 10.9 Cg_exo -71.55 143.94 43.7 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.809 2.34 . . . . 0.0 112.071 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.91 -175.01 0.09 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.159 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.238 -0.887 . . . . 0.0 111.119 -179.978 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -131.77 32.08 4.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.836 0.35 . . . . 0.0 111.108 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -139.8 -45.15 0.44 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.251 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.0 tp -116.35 -31.25 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.47 -11.51 82.55 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.473 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -116.8 36.7 4.07 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.825 0.345 . . . . 0.0 110.842 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -117.69 37.49 3.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.148 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 37.1 p-90 -109.63 -37.99 5.54 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.22 0.534 . . . . 0.0 110.505 179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.699 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -55.38 -42.41 95.81 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.47 -179.185 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.699 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.2 Cg_endo -41.99 -28.36 0.79 Allowed 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 122.336 2.024 . . . . 0.0 111.707 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -55.7 -39.31 70.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.903 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -78.94 -33.3 45.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.201 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 125.99 102.1 1.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.481 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.77 -44.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.665 2.244 . . . . 0.0 112.414 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 61.85 166.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.101 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.159 -0.924 . . . . 0.0 111.069 179.913 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.55 -0.22 . . . . 0.0 112.55 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -100.97 24.31 9.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.686 0.279 . . . . 0.0 111.203 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.16 -29.24 6.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.187 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -76.05 -6.75 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.443 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.8 -5.57 14.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.248 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.454 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 49.7 tp -95.25 49.13 1.19 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.183 0.516 . . . . 0.0 110.365 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -103.49 34.42 2.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.144 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 38.8 p-90 -125.01 -35.67 2.63 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.416 0.627 . . . . 0.0 110.146 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.755 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.3 tt -62.47 -36.89 30.85 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.082 -0.963 . . . . 0.0 112.894 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.755 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.8 Cg_endo -39.91 -28.82 0.27 Allowed 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.493 2.129 . . . . 0.0 112.237 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -59.19 -45.49 90.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.344 178.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -81.84 -34.29 30.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 143.49 107.19 0.58 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.524 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.21 88.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.548 2.165 . . . . 0.0 112.401 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 53.63 -167.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.246 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.001 179.931 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.127 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.62 42.67 16.87 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.848 0.356 . . . . 0.0 111.148 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 -35.56 30.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.11 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.8 pt -87.87 9.82 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.729 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.17 24.31 76.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.302 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.439 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 48.1 tp -92.58 49.71 1.51 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.141 0.496 . . . . 0.0 110.538 -179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -120.73 42.59 2.98 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.63 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 35.9 p-90 -122.01 -34.5 3.34 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.442 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.746 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.1 tt -61.69 -38.13 47.47 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.784 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.746 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.6 Cg_endo -42.65 -26.27 0.61 Allowed 'Trans proline' 0 C--N 1.355 0.889 0 C-N-CA 122.331 2.021 . . . . 0.0 112.008 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -58.44 -47.73 83.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.733 178.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -71.91 -22.4 61.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.396 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 155.17 107.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.7 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -76.55 148.91 29.98 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 122.507 2.138 . . . . 0.0 112.261 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 59.5 -173.15 0.11 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.098 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.226 -0.892 . . . . 0.0 111.071 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.139 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.17 30.38 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.778 0.323 . . . . 0.0 111.092 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.92 -50.23 6.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.111 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 31.4 pt -82.73 2.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.571 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.21 15.99 70.52 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.297 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 53.7 tp -107.6 62.35 0.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.022 0.439 . . . . 0.0 110.569 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -127.95 34.97 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.987 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 33.2 p-90 -126.55 -35.71 2.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.345 0.593 . . . . 0.0 110.204 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.748 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.1 tt -62.17 -37.24 35.71 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.92 -179.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.748 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.5 Cg_endo -40.39 -28.31 0.3 Allowed 'Trans proline' 0 C--N 1.356 0.971 0 C-N-CA 122.406 2.071 . . . . 0.0 112.081 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -60.16 -47.23 86.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 178.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 8.2 m-30 -58.98 -30.75 68.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.88 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 142.37 -88.46 0.18 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.451 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.35 113.67 3.78 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.634 2.222 . . . . 0.0 112.361 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -112.82 69.55 0.69 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.117 -179.987 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.654 -0.178 . . . . 0.0 112.654 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.92 -41.97 3.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.879 0.371 . . . . 0.0 111.143 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -68.91 -56.2 8.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.017 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 50.4 mm -119.01 -6.92 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.137 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.72 54.34 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.742 -178.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.432 ' N ' ' CD1' ' A' ' 6' ' ' LEU . 3.8 mp -129.54 26.26 5.36 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.715 0.293 . . . . 0.0 110.675 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.25 39.74 1.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.135 0.493 . . . . 0.0 111.216 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.1 p-90 -124.21 -35.79 2.76 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.466 0.651 . . . . 0.0 110.284 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.734 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.8 tt -58.98 -39.08 71.38 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.719 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.734 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 3.8 Cg_endo -43.55 -28.57 1.8 Allowed 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 122.173 1.915 . . . . 0.0 111.532 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -49.23 -47.79 46.08 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.57 178.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -74.26 -29.63 61.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.831 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -117.63 65.3 0.36 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 132.99 21.06 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.602 2.202 . . . . 0.0 112.306 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.84 30.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.164 -0.922 . . . . 0.0 111.056 179.957 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.35 31.17 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 111.075 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.85 -51.97 2.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.147 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 50.1 mm -116.85 -11.71 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.219 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 77.84 0.09 73.66 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.965 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.51 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 44.3 tp -141.54 26.13 1.96 Allowed 'General case' 0 CA--C 1.528 0.115 0 CA-C-O 120.98 0.419 . . . . 0.0 110.643 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.23 47.44 1.08 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.072 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 34.9 p-90 -126.84 -35.25 2.31 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.345 0.593 . . . . 0.0 110.367 179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.757 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -62.75 -37.21 32.16 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 115.091 -0.959 . . . . 0.0 112.948 -179.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.757 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.1 Cg_endo -40.95 -27.54 0.32 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.452 2.101 . . . . 0.0 111.995 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.3 m-85 -60.54 -46.91 88.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.524 178.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -77.15 -23.84 51.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.217 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.38 -107.24 0.01 OUTLIER Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.597 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.83 -179.78 1.46 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.556 2.171 . . . . 0.0 112.258 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -88.44 81.21 7.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.129 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.084 179.97 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 60.78 30.56 19.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.831 0.348 . . . . 0.0 111.073 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.4 -70.01 0.81 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.046 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.427 HG23 ' N ' ' A' ' 5' ' ' GLY . 7.4 tp -142.91 -42.27 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.013 0.435 . . . . 0.0 111.253 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.427 ' N ' HG23 ' A' ' 4' ' ' ILE . . . -53.9 -23.48 23.1 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.545 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.523 HD12 ' NE1' ' A' ' 8' ' ' TRP . 55.3 tp -120.77 62.84 0.87 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.998 0.428 . . . . 0.0 110.694 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -120.91 44.11 2.59 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.286 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.523 ' NE1' HD12 ' A' ' 6' ' ' LEU . 46.3 p-90 -125.29 -34.59 2.7 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.44 0.638 . . . . 0.0 110.235 179.614 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.77 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.5 tt -62.97 -36.05 22.55 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.123 -0.944 . . . . 0.0 113.041 -179.015 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.77 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.2 Cg_endo -39.99 -27.53 0.22 Allowed 'Trans proline' 0 C--N 1.358 1.073 0 C-N-CA 122.316 2.011 . . . . 0.0 112.531 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.57 -37.74 82.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.582 179.015 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -84.28 -30.76 25.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.577 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 137.38 121.79 2.05 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.361 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -50.79 -39.8 57.44 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.51 2.14 . . . . 0.0 112.319 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -102.93 55.42 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.961 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.027 -179.811 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.87 -33.63 34.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.776 0.322 . . . . 0.0 111.069 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.54 69.0 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.1 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.4 pt -82.28 0.97 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.613 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.791 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 123.43 -18.48 7.74 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.412 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.791 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.7 mp -126.33 42.09 3.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.805 0.335 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.25 19.78 17.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.434 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 36.6 p-90 -112.44 -38.32 4.7 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.073 0.463 . . . . 0.0 110.6 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.754 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -54.1 -42.79 95.33 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.606 -179.052 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.707 ' HD3' HG23 ' A' ' 9' ' ' ILE . 1.1 Cg_endo -41.96 -28.45 0.79 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.29 1.993 . . . . 0.0 111.714 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.6 m-30 -54.84 -39.1 68.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.877 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -81.49 -30.17 33.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.971 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 151.36 109.51 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.533 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -68.8 -27.57 31.2 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.444 2.096 . . . . 0.0 112.324 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.89 -20.72 25.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.332 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.216 -0.897 . . . . 0.0 111.132 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 61.77 64.34 1.04 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.948 0.404 . . . . 0.0 111.001 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -172.21 -78.15 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.077 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 59.2 mt -114.29 -19.03 7.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.273 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 121.29 -16.84 9.14 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.532 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.514 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 43.7 tp -151.54 31.38 0.58 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.998 0.428 . . . . 0.0 110.425 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.71 40.9 1.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.9 p-90 -126.72 -34.21 2.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.276 0.56 . . . . 0.0 110.419 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.756 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -62.07 -37.65 40.37 Favored Pre-proline 0 N--CA 1.451 -0.395 0 CA-C-N 115.254 -0.884 . . . . 0.0 112.987 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.756 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.3 Cg_endo -41.78 -26.19 0.41 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.215 1.943 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.07 -38.02 81.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -75.99 -27.63 57.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -135.06 72.99 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.551 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.62 -71.92 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.672 2.248 . . . . 0.0 112.27 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.77 97.12 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.115 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.05 179.979 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.209 0 N-CA-C 112.396 -0.281 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.75 -43.32 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.785 0.326 . . . . 0.0 111.162 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.06 51.96 6.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.027 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 52.6 mt -110.73 -17.74 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.137 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 94.08 3.78 63.46 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.391 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.52 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 44.2 tp -159.07 29.15 0.21 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.038 0.446 . . . . 0.0 110.516 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -92.73 22.12 5.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.438 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.461 ' CZ3' ' CZ ' ' A' ' 12' ' ' PHE . 23.9 p-90 -107.03 -38.37 6.05 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.629 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.79 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -55.44 -42.36 95.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.792 179.641 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.716 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.3 Cg_endo -43.07 -29.63 1.69 Allowed 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 121.849 1.699 . . . . 0.0 110.678 178.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.409 ' CG ' ' O ' ' A' ' 8' ' ' TRP . 8.8 m-30 -56.21 -54.3 46.9 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.539 178.582 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' CE1' HG12 ' A' ' 9' ' ' ILE . 6.4 p90 -106.16 20.56 18.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.985 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -167.84 73.66 0.14 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.576 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.04 -62.39 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.631 2.221 . . . . 0.0 112.227 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.73 70.81 2.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.973 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.281 -0.866 . . . . 0.0 111.061 179.936 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 112.579 -0.209 . . . . 0.0 112.579 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.14 30.14 0.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 111.203 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -67.87 -44.77 76.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.535 HG22 ' O ' ' A' ' 4' ' ' ILE . 49.8 mm -118.69 -7.64 11.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.207 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.83 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 88.75 -15.97 55.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.384 -0.912 . . . . 0.0 111.583 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.83 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.9 mp -129.73 24.08 5.39 Favored 'General case' 0 N--CA 1.458 -0.069 0 CA-C-O 120.737 0.303 . . . . 0.0 110.897 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -116.58 60.73 0.73 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.014 0.435 . . . . 0.0 111.1 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 39.7 p-90 -129.34 -36.07 1.72 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.476 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.74 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.8 tt -58.99 -38.81 68.68 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.815 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.74 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -40.85 -29.4 0.44 Allowed 'Trans proline' 0 C--N 1.357 1.008 0 C-N-CA 122.243 1.962 . . . . 0.0 111.84 179.731 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 9.1 m-30 -53.84 -44.84 70.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.699 178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -79.46 -0.59 33.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.642 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.25 57.46 0.48 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.539 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.3 107.49 1.78 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.524 2.15 . . . . 0.0 112.305 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -131.64 -81.86 0.51 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.172 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.226 -0.892 . . . . 0.0 111.187 179.991 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.161 0 N-CA-C 112.519 -0.233 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -167.98 -43.13 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.828 0.347 . . . . 0.0 111.097 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.5 64.46 1.33 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.124 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 57.2 mt -112.98 -17.44 8.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.466 ' O ' HD23 ' A' ' 6' ' ' LEU . . . 109.84 -12.23 32.25 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.408 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.466 HD23 ' O ' ' A' ' 5' ' ' GLY . 88.3 mt -135.91 16.78 3.28 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.692 0.282 . . . . 0.0 111.236 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.16 36.05 2.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.976 0.417 . . . . 0.0 111.065 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.4 p-90 -126.88 -34.57 2.36 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.267 0.556 . . . . 0.0 110.403 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.759 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -61.9 -37.43 39.17 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.021 -178.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.759 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.3 Cg_endo -41.48 -26.41 0.37 Allowed 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 122.358 2.039 . . . . 0.0 112.214 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -60.21 -38.18 82.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.75 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -76.45 -27.83 56.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.796 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.17 90.12 0.53 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.439 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 173.21 11.33 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.632 2.222 . . . . 0.0 112.288 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -109.72 136.95 48.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.143 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.097 -180.0 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 112.438 -0.265 . . . . 0.0 112.438 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.1 25.48 13.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.818 0.342 . . . . 0.0 111.291 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -177.46 37.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 pt -85.14 6.51 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.913 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.484 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 103.25 -13.24 55.22 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.748 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.602 ' N ' HD12 ' A' ' 6' ' ' LEU . 4.5 mp -106.2 61.37 0.65 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.971 0.415 . . . . 0.0 111.091 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -103.12 26.91 7.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.012 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 40.8 p-90 -129.47 -37.78 1.58 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.318 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.723 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.6 tt -54.14 -39.88 77.67 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.691 -179.27 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.723 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.1 Cg_endo -42.08 -29.07 0.96 Allowed 'Trans proline' 0 C--N 1.355 0.907 0 C-N-CA 122.26 1.973 . . . . 0.0 111.908 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.655 ' O ' ' HB2' ' A' ' 15' ' ' ALA . 8.8 m-30 -48.21 -45.69 34.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.707 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 50.0 m-85 -75.2 -28.18 59.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.858 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.17 -114.63 0.03 OUTLIER Glycine 0 CA--C 1.519 0.294 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.548 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.66 -63.38 0.11 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.491 2.128 . . . . 0.0 112.34 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' A' ' 11' ' ' TYR . . . 58.91 74.7 0.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.09 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.992 -179.958 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -127.67 34.87 4.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.738 0.304 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.73 35.51 1.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.045 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.8 tt -103.85 -20.39 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.278 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.95 12.44 25.88 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.7 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.631 ' N ' HD12 ' A' ' 6' ' ' LEU . 4.1 mp 46.82 29.73 1.06 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 111.31 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.76 39.54 2.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.118 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.4 p-90 -112.54 -35.35 5.56 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.647 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.76 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -64.91 -38.87 33.08 Favored Pre-proline 0 C--N 1.324 -0.503 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.145 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.76 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.7 -30.25 1.01 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 122.35 2.034 . . . . 0.0 111.536 179.811 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -64.01 -52.84 57.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.553 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -65.22 -15.18 62.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.13 105.97 3.05 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.626 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.52 154.11 12.51 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.395 2.063 . . . . 0.0 112.287 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -105.6 -178.45 3.65 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.143 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.36 -0.829 . . . . 0.0 111.039 179.987 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 61.25 29.94 18.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 111.157 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -176.15 -71.68 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.032 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.726 HG23 ' H ' ' A' ' 6' ' ' LEU . 11.3 tt -116.33 -14.89 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.225 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.782 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 98.95 -10.39 62.09 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.248 -179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.782 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.7 mp -126.28 15.25 7.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.693 0.282 . . . . 0.0 111.063 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -95.0 41.34 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.99 0.424 . . . . 0.0 111.291 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 51.1 p-90 -125.32 -35.05 2.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.251 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.747 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 7.1 tt -58.51 -38.45 65.65 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 115.153 -0.93 . . . . 0.0 112.865 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.747 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.1 Cg_endo -40.04 -29.66 0.35 Allowed 'Trans proline' 0 C--N 1.357 1.0 0 C-N-CA 122.329 2.019 . . . . 0.0 112.11 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -52.44 -36.3 54.22 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.713 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -81.9 -34.11 30.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.729 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.44 78.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.634 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.23 158.59 55.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.62 2.214 . . . . 0.0 112.296 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -109.54 145.37 36.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.134 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.24 -42.85 2.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.704 0.287 . . . . 0.0 111.144 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.21 -84.05 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.115 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.692 HG22 ' HB2' ' A' ' 7' ' ' ALA . 11.6 tt -126.93 -17.82 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.731 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.29 -10.67 36.5 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.571 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.625 ' H ' HG23 ' A' ' 4' ' ' ILE . 44.5 tp -155.13 29.74 0.4 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.086 0.47 . . . . 0.0 110.542 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.692 ' HB2' HG22 ' A' ' 4' ' ' ILE . . . -97.39 43.94 1.06 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 36.7 p-90 -126.81 -32.78 2.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.806 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 5.5 tt -69.1 -33.02 3.71 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.806 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.7 Cg_endo -39.48 -31.74 0.4 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.477 2.118 . . . . 0.0 112.188 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 -62.19 -48.69 78.93 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.438 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.409 ' N ' ' O ' ' A' ' 9' ' ' ILE . 8.4 m-30 -59.32 -19.58 47.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.619 179.078 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.08 -73.64 0.38 Allowed Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.644 -179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -68.1 -24.06 39.14 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.475 2.117 . . . . 0.0 112.381 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.68 50.99 1.9 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.131 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.288 -0.863 . . . . 0.0 111.12 -179.975 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 60.43 32.59 20.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.847 0.356 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.49 -57.35 4.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.5 HG23 ' H ' ' A' ' 6' ' ' LEU . 7.1 tp -113.63 -17.13 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.236 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.635 ' O ' HD23 ' A' ' 6' ' ' LEU . . . 118.24 -17.99 11.33 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.362 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.635 HD23 ' O ' ' A' ' 5' ' ' GLY . 89.0 mt -144.74 24.01 1.54 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.704 0.288 . . . . 0.0 110.957 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -107.37 33.36 4.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.993 0.425 . . . . 0.0 111.067 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.405 ' O ' ' CG ' ' A' ' 11' ' ' TYR . 42.0 p-90 -109.8 -37.6 5.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.399 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.749 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -53.43 -42.97 94.45 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.54 -0.755 . . . . 0.0 112.276 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.717 ' HD3' HG23 ' A' ' 9' ' ' ILE . 1.0 OUTLIER -42.47 -28.13 0.93 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.233 1.955 . . . . 0.0 111.721 179.451 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.405 ' CG ' ' O ' ' A' ' 8' ' ' TRP . 8.7 m-30 -52.9 -36.73 59.77 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.838 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -70.31 -37.03 74.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.901 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 56.93 103.0 0.01 OUTLIER Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.563 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.67 126.23 13.76 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.516 2.144 . . . . 0.0 112.279 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -102.16 102.48 12.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.024 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.229 -0.891 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.199 0 N-CA-C 112.576 -0.209 . . . . 0.0 112.576 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.46 45.82 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.906 0.384 . . . . 0.0 111.016 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.76 -14.61 13.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.41 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.0 tp -119.74 -36.44 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.001 0.429 . . . . 0.0 111.099 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.782 ' C ' HD12 ' A' ' 6' ' ' LEU . . . -60.3 -22.17 58.09 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.229 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.782 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.7 mp -126.11 31.04 5.51 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.791 0.329 . . . . 0.0 110.766 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.42 14.95 30.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.591 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 35.2 p-90 -111.3 -39.35 4.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.155 0.502 . . . . 0.0 110.61 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.76 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -53.62 -42.72 93.67 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.444 -179.18 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.707 ' HD3' HG23 ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.9 -28.5 0.77 Allowed 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.26 1.973 . . . . 0.0 111.781 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -54.88 -39.18 68.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.89 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -79.5 -32.67 42.44 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.124 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.76 99.88 2.03 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.575 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 10' ' ' PRO . 24.1 Cg_exo -64.02 91.99 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.525 2.15 . . . . 0.0 112.19 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -146.32 74.32 1.36 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.116 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.114 179.997 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.134 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.74 35.98 4.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 111.12 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.65 -45.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.134 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.801 HG23 ' H ' ' A' ' 6' ' ' LEU . 11.0 tt -117.61 -14.6 9.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.186 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.808 ' C ' HD22 ' A' ' 6' ' ' LEU . . . 86.82 -3.22 87.17 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.129 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.808 HD22 ' C ' ' A' ' 5' ' ' GLY . 2.3 mm? -130.53 27.31 5.01 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.849 0.357 . . . . 0.0 110.734 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -92.65 48.72 1.39 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.713 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 39.9 p-90 -118.81 -37.31 3.27 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.812 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.749 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.7 tt -58.09 -38.91 71.55 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.652 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.749 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.0 -29.82 0.52 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.369 2.046 . . . . 0.0 111.763 179.428 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.6 m-30 -51.14 -45.42 61.63 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.475 178.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -83.02 -31.19 27.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.95 94.57 0.11 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.438 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.87 132.73 51.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.545 2.163 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.56 -176.9 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.207 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.149 -0.929 . . . . 0.0 111.072 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.168 0 N-CA-C 112.61 -0.196 . . . . 0.0 112.61 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.21 -30.59 20.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.854 0.359 . . . . 0.0 111.175 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.55 -76.7 0.58 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.982 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.9 tt -110.55 -20.28 6.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.96 -15.77 4.01 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.702 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 90.9 mt 52.29 33.93 13.71 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.815 0.341 . . . . 0.0 111.112 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -98.95 30.63 3.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.013 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.401 ' C ' ' HD2' ' A' ' 10' ' ' PRO . 52.7 p-90 -124.95 -36.55 2.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.32 0.581 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.728 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 7.3 tt -56.33 -38.98 74.32 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.886 -179.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.728 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.2 Cg_endo -40.15 -29.1 0.31 Allowed 'Trans proline' 0 C--N 1.358 1.029 0 C-N-CA 122.331 2.021 . . . . 0.0 112.112 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.1 m-30 -51.92 -33.01 35.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.747 179.183 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.408 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 4.4 m-85 -92.41 -34.29 14.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.275 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.32 104.86 0.53 Allowed Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.673 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.408 ' HD3' ' O ' ' A' ' 12' ' ' PHE . 10.9 Cg_exo -71.55 143.94 43.7 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.809 2.34 . . . . 0.0 112.071 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.91 -175.01 0.09 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.159 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.238 -0.887 . . . . 0.0 111.119 -179.978 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.535 ' HA ' HD12 ' A' ' 6' ' ' LEU . . . -131.77 32.08 4.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.836 0.35 . . . . 0.0 111.108 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -139.8 -45.15 0.44 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.251 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.0 tp -116.35 -31.25 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.47 -11.51 82.55 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.473 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.535 HD12 ' HA ' ' A' ' 2' ' ' ALA . 86.6 mt -116.8 36.7 4.07 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.825 0.345 . . . . 0.0 110.842 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -117.69 37.49 3.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.148 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 37.1 p-90 -109.63 -37.99 5.54 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.22 0.534 . . . . 0.0 110.505 179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.752 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -55.38 -42.41 95.81 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.47 -179.185 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.709 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.2 Cg_endo -41.99 -28.36 0.79 Allowed 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 122.336 2.024 . . . . 0.0 111.707 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -55.7 -39.31 70.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.903 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -78.94 -33.3 45.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.201 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 125.99 102.1 1.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.481 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 10' ' ' PRO . 85.2 Cg_endo -83.77 -44.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.665 2.244 . . . . 0.0 112.414 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 61.85 166.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.101 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.159 -0.924 . . . . 0.0 111.069 179.913 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.55 -0.22 . . . . 0.0 112.55 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -100.97 24.31 9.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.686 0.279 . . . . 0.0 111.203 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.16 -29.24 6.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.187 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -76.05 -6.75 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.443 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.8 -5.57 14.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.248 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.473 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 49.7 tp -95.25 49.13 1.19 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.183 0.516 . . . . 0.0 110.365 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -103.49 34.42 2.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.144 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.46 ' NE1' HD12 ' A' ' 6' ' ' LEU . 38.8 p-90 -125.01 -35.67 2.63 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.416 0.627 . . . . 0.0 110.146 179.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.763 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.3 tt -62.47 -36.89 30.85 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.082 -0.963 . . . . 0.0 112.894 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.763 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.8 Cg_endo -39.91 -28.82 0.27 Allowed 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.493 2.129 . . . . 0.0 112.237 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -59.19 -45.49 90.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.344 178.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -81.84 -34.29 30.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 143.49 107.19 0.58 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.524 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.21 88.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.548 2.165 . . . . 0.0 112.401 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 53.63 -167.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.246 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.001 179.931 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.127 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.62 42.67 16.87 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.848 0.356 . . . . 0.0 111.148 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 -35.56 30.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.11 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.8 pt -87.87 9.82 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.729 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.17 24.31 76.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.302 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.458 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 48.1 tp -92.58 49.71 1.51 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.141 0.496 . . . . 0.0 110.538 -179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -120.73 42.59 2.98 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.63 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 35.9 p-90 -122.01 -34.5 3.34 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.442 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.753 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.1 tt -61.69 -38.13 47.47 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.784 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.753 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.6 Cg_endo -42.65 -26.27 0.61 Allowed 'Trans proline' 0 C--N 1.355 0.889 0 C-N-CA 122.331 2.021 . . . . 0.0 112.008 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -58.44 -47.73 83.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.733 178.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -71.91 -22.4 61.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.396 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 155.17 107.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.7 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -76.55 148.91 29.98 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 122.507 2.138 . . . . 0.0 112.261 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 59.5 -173.15 0.11 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.098 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.226 -0.892 . . . . 0.0 111.071 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.139 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.17 30.38 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.778 0.323 . . . . 0.0 111.092 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.92 -50.23 6.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.111 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 31.4 pt -82.73 2.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.571 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.21 15.99 70.52 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.297 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.566 HD11 HG21 ' A' ' 9' ' ' ILE . 53.7 tp -107.6 62.35 0.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.022 0.439 . . . . 0.0 110.569 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -127.95 34.97 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.987 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 33.2 p-90 -126.55 -35.71 2.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.345 0.593 . . . . 0.0 110.204 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.755 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.1 tt -62.17 -37.24 35.71 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.92 -179.251 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.755 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.5 Cg_endo -40.39 -28.31 0.3 Allowed 'Trans proline' 0 C--N 1.356 0.971 0 C-N-CA 122.406 2.071 . . . . 0.0 112.081 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -60.16 -47.23 86.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 178.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 8.2 m-30 -58.98 -30.75 68.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.88 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 142.37 -88.46 0.18 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.451 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.35 113.67 3.78 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.634 2.222 . . . . 0.0 112.361 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.668 ' HB2' ' HA ' ' A' ' 10' ' ' PRO . . . -112.82 69.55 0.69 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.117 -179.987 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.654 -0.178 . . . . 0.0 112.654 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.92 -41.97 3.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.879 0.371 . . . . 0.0 111.143 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -68.91 -56.2 8.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.017 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.536 HG22 ' O ' ' A' ' 4' ' ' ILE . 50.4 mm -119.01 -6.92 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.137 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 86.52 -14.72 54.34 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.742 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.823 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.8 mp -129.54 26.26 5.36 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.715 0.293 . . . . 0.0 110.675 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.25 39.74 1.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.135 0.493 . . . . 0.0 111.216 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.1 p-90 -124.21 -35.79 2.76 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.466 0.651 . . . . 0.0 110.284 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.746 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.8 tt -58.98 -39.08 71.38 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.719 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.746 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 3.8 Cg_endo -43.55 -28.57 1.8 Allowed 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 122.173 1.915 . . . . 0.0 111.532 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -49.23 -47.79 46.08 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.57 178.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -74.26 -29.63 61.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.831 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -117.63 65.3 0.36 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 132.99 21.06 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.602 2.202 . . . . 0.0 112.306 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.84 30.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.164 -0.922 . . . . 0.0 111.056 179.957 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.35 31.17 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 111.075 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.85 -51.97 2.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.147 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.468 HG22 ' O ' ' A' ' 4' ' ' ILE . 50.1 mm -116.85 -11.71 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.219 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 77.84 0.09 73.66 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.965 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.531 ' O ' ' HG ' ' A' ' 6' ' ' LEU . 44.3 tp -141.54 26.13 1.96 Allowed 'General case' 0 CA--C 1.528 0.115 0 CA-C-O 120.98 0.419 . . . . 0.0 110.643 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.23 47.44 1.08 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.072 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.519 ' NE1' HD12 ' A' ' 6' ' ' LEU . 34.9 p-90 -126.84 -35.25 2.31 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.345 0.593 . . . . 0.0 110.367 179.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.769 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -62.75 -37.21 32.16 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 115.091 -0.959 . . . . 0.0 112.948 -179.143 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.769 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.1 Cg_endo -40.95 -27.54 0.32 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.452 2.101 . . . . 0.0 111.995 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.3 m-85 -60.54 -46.91 88.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.524 178.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -77.15 -23.84 51.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.217 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.38 -107.24 0.01 OUTLIER Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.597 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.83 -179.78 1.46 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.556 2.171 . . . . 0.0 112.258 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -88.44 81.21 7.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.129 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.084 179.97 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 60.78 30.56 19.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.831 0.348 . . . . 0.0 111.073 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.4 -70.01 0.81 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.046 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.427 HG23 ' N ' ' A' ' 5' ' ' GLY . 7.4 tp -142.91 -42.27 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 121.013 0.435 . . . . 0.0 111.253 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.427 ' N ' HG23 ' A' ' 4' ' ' ILE . . . -53.9 -23.48 23.1 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.545 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.523 HD12 ' NE1' ' A' ' 8' ' ' TRP . 55.3 tp -120.77 62.84 0.87 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.998 0.428 . . . . 0.0 110.694 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -120.91 44.11 2.59 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.286 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.523 ' NE1' HD12 ' A' ' 6' ' ' LEU . 46.3 p-90 -125.29 -34.59 2.7 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.44 0.638 . . . . 0.0 110.235 179.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.77 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.5 tt -62.97 -36.05 22.55 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.123 -0.944 . . . . 0.0 113.041 -179.015 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.77 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.2 Cg_endo -39.99 -27.53 0.22 Allowed 'Trans proline' 0 C--N 1.358 1.073 0 C-N-CA 122.316 2.011 . . . . 0.0 112.531 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.57 -37.74 82.3 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.582 179.015 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -84.28 -30.76 25.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.577 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 137.38 121.79 2.05 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.361 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -50.79 -39.8 57.44 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.51 2.14 . . . . 0.0 112.319 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -102.93 55.42 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.961 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.027 -179.811 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.87 -33.63 34.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.776 0.322 . . . . 0.0 111.069 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.54 69.0 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.1 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.4 pt -82.28 0.97 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.613 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.791 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 123.43 -18.48 7.74 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.412 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.791 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.7 mp -126.33 42.09 3.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.805 0.335 . . . . 0.0 110.9 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.25 19.78 17.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.434 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 36.6 p-90 -112.44 -38.32 4.7 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.073 0.463 . . . . 0.0 110.6 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.754 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -54.1 -42.79 95.33 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.606 -179.052 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.707 ' HD3' HG23 ' A' ' 9' ' ' ILE . 1.1 Cg_endo -41.96 -28.45 0.79 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.29 1.993 . . . . 0.0 111.714 179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.6 m-30 -54.84 -39.1 68.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.877 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -81.49 -30.17 33.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.971 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 151.36 109.51 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.533 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -68.8 -27.57 31.2 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.444 2.096 . . . . 0.0 112.324 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.89 -20.72 25.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.332 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.216 -0.897 . . . . 0.0 111.132 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 61.77 64.34 1.04 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.948 0.404 . . . . 0.0 111.001 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -172.21 -78.15 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.077 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 59.2 mt -114.29 -19.03 7.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.273 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 121.29 -16.84 9.14 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.532 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.514 ' HG ' ' O ' ' A' ' 6' ' ' LEU . 43.7 tp -151.54 31.38 0.58 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.998 0.428 . . . . 0.0 110.425 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.71 40.9 1.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.081 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.9 p-90 -126.72 -34.21 2.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.276 0.56 . . . . 0.0 110.419 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.756 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -62.07 -37.65 40.37 Favored Pre-proline 0 N--CA 1.451 -0.395 0 CA-C-N 115.254 -0.884 . . . . 0.0 112.987 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.756 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.3 Cg_endo -41.78 -26.19 0.41 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 122.215 1.943 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.07 -38.02 81.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -75.99 -27.63 57.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -135.06 72.99 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.551 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.62 -71.92 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.672 2.248 . . . . 0.0 112.27 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.77 97.12 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.115 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.05 179.979 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.209 0 N-CA-C 112.396 -0.281 . . . . 0.0 112.396 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -112.75 -43.32 3.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.785 0.326 . . . . 0.0 111.162 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.06 51.96 6.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.027 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 52.6 mt -110.73 -17.74 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.137 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 94.08 3.78 63.46 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.391 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.52 ' HG ' ' O ' ' A' ' 6' ' ' LEU . 44.2 tp -159.07 29.15 0.21 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.038 0.446 . . . . 0.0 110.516 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -92.73 22.12 5.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.438 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.461 ' CZ3' ' CZ ' ' A' ' 12' ' ' PHE . 23.9 p-90 -107.03 -38.37 6.05 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.629 179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.79 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -55.44 -42.36 95.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.792 179.641 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.716 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.3 Cg_endo -43.07 -29.63 1.69 Allowed 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 121.849 1.699 . . . . 0.0 110.678 178.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.409 ' CG ' ' O ' ' A' ' 8' ' ' TRP . 8.8 m-30 -56.21 -54.3 46.9 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.539 178.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' CE1' HG12 ' A' ' 9' ' ' ILE . 6.4 p90 -106.16 20.56 18.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.985 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -167.84 73.66 0.14 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.576 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.04 -62.39 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.631 2.221 . . . . 0.0 112.227 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.73 70.81 2.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.973 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.281 -0.866 . . . . 0.0 111.061 179.936 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 112.579 -0.209 . . . . 0.0 112.579 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.14 30.14 0.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 111.203 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -67.87 -44.77 76.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.535 ' O ' HG22 ' A' ' 4' ' ' ILE . 49.8 mm -118.69 -7.64 11.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.207 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.83 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 88.75 -15.97 55.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.384 -0.912 . . . . 0.0 111.583 -178.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.83 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.9 mp -129.73 24.08 5.39 Favored 'General case' 0 N--CA 1.458 -0.069 0 CA-C-O 120.737 0.303 . . . . 0.0 110.897 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -116.58 60.73 0.73 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.014 0.435 . . . . 0.0 111.1 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 39.7 p-90 -129.34 -36.07 1.72 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.476 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.74 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.8 tt -58.99 -38.81 68.68 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.815 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.74 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -40.85 -29.4 0.44 Allowed 'Trans proline' 0 C--N 1.357 1.008 0 C-N-CA 122.243 1.962 . . . . 0.0 111.84 179.731 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 9.1 m-30 -53.84 -44.84 70.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.699 178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -79.46 -0.59 33.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.642 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -115.25 57.46 0.48 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.539 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.3 107.49 1.78 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.524 2.15 . . . . 0.0 112.305 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -131.64 -81.86 0.51 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.172 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.226 -0.892 . . . . 0.0 111.187 179.991 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.161 0 N-CA-C 112.519 -0.233 . . . . 0.0 112.519 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -167.98 -43.13 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.828 0.347 . . . . 0.0 111.097 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 59.5 64.46 1.33 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.124 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 57.2 mt -112.98 -17.44 8.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.105 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.466 ' O ' HD23 ' A' ' 6' ' ' LEU . . . 109.84 -12.23 32.25 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.408 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.466 HD23 ' O ' ' A' ' 5' ' ' GLY . 88.3 mt -135.91 16.78 3.28 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.692 0.282 . . . . 0.0 111.236 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.16 36.05 2.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.976 0.417 . . . . 0.0 111.065 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.4 p-90 -126.88 -34.57 2.36 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.267 0.556 . . . . 0.0 110.403 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.759 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -61.9 -37.43 39.17 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.021 -178.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.759 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.3 Cg_endo -41.48 -26.41 0.37 Allowed 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 122.358 2.039 . . . . 0.0 112.214 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -60.21 -38.18 82.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.75 178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -76.45 -27.83 56.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.796 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -114.17 90.12 0.53 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.439 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 173.21 11.33 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.632 2.222 . . . . 0.0 112.288 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -109.72 136.95 48.24 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.143 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.097 -180.0 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 112.438 -0.265 . . . . 0.0 112.438 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.1 25.48 13.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.818 0.342 . . . . 0.0 111.291 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -177.46 37.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.6 pt -85.14 6.51 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.913 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.484 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 103.25 -13.24 55.22 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.748 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.602 HD12 ' N ' ' A' ' 6' ' ' LEU . 4.5 mp -106.2 61.37 0.65 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.971 0.415 . . . . 0.0 111.091 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -103.12 26.91 7.68 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.012 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 40.8 p-90 -129.47 -37.78 1.58 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.318 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.723 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.6 tt -54.14 -39.88 77.67 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.691 -179.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.723 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.1 Cg_endo -42.08 -29.07 0.96 Allowed 'Trans proline' 0 C--N 1.355 0.907 0 C-N-CA 122.26 1.973 . . . . 0.0 111.908 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.655 ' O ' ' HB2' ' A' ' 15' ' ' ALA . 8.8 m-30 -48.21 -45.69 34.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.707 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 50.0 m-85 -75.2 -28.18 59.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.858 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.17 -114.63 0.03 OUTLIER Glycine 0 CA--C 1.519 0.294 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.548 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.66 -63.38 0.11 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.491 2.128 . . . . 0.0 112.34 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.655 ' HB2' ' O ' ' A' ' 11' ' ' TYR . . . 58.91 74.7 0.43 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.09 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.992 -179.958 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -127.67 34.87 4.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.738 0.304 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.73 35.51 1.28 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.045 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.8 tt -103.85 -20.39 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.278 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.95 12.44 25.88 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.7 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.631 HD12 ' N ' ' A' ' 6' ' ' LEU . 4.1 mp 46.82 29.73 1.06 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.85 0.357 . . . . 0.0 111.31 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.76 39.54 2.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.118 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.4 p-90 -112.54 -35.35 5.56 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.647 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.76 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -64.91 -38.87 33.08 Favored Pre-proline 0 C--N 1.324 -0.503 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -179.145 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.76 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.7 -30.25 1.01 Allowed 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 122.35 2.034 . . . . 0.0 111.536 179.811 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -64.01 -52.84 57.63 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.553 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -65.22 -15.18 62.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.894 179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.13 105.97 3.05 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.626 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.52 154.11 12.51 Favored 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.395 2.063 . . . . 0.0 112.287 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -105.6 -178.45 3.65 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.143 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.36 -0.829 . . . . 0.0 111.039 179.987 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 112.525 -0.23 . . . . 0.0 112.525 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 61.25 29.94 18.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 111.157 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -176.15 -71.68 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.032 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.726 HG23 ' H ' ' A' ' 6' ' ' LEU . 11.3 tt -116.33 -14.89 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.225 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.782 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 98.95 -10.39 62.09 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.248 -179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.782 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.7 mp -126.28 15.25 7.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.693 0.282 . . . . 0.0 111.063 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -95.0 41.34 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.99 0.424 . . . . 0.0 111.291 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 51.1 p-90 -125.32 -35.05 2.64 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.251 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.747 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 7.1 tt -58.51 -38.45 65.65 Favored Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 115.153 -0.93 . . . . 0.0 112.865 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.747 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.1 Cg_endo -40.04 -29.66 0.35 Allowed 'Trans proline' 0 C--N 1.357 1.0 0 C-N-CA 122.329 2.019 . . . . 0.0 112.11 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -52.44 -36.3 54.22 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.713 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -81.9 -34.11 30.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.729 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.44 78.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.634 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.23 158.59 55.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.62 2.214 . . . . 0.0 112.296 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -109.54 145.37 36.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.134 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.24 -42.85 2.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.704 0.287 . . . . 0.0 111.144 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.21 -84.05 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.115 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.692 HG22 ' HB2' ' A' ' 7' ' ' ALA . 11.6 tt -126.93 -17.82 2.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.731 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.29 -10.67 36.5 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.571 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.625 ' H ' HG23 ' A' ' 4' ' ' ILE . 44.5 tp -155.13 29.74 0.4 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.086 0.47 . . . . 0.0 110.542 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.692 ' HB2' HG22 ' A' ' 4' ' ' ILE . . . -97.39 43.94 1.06 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 36.7 p-90 -126.81 -32.78 2.55 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.806 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 5.5 tt -69.1 -33.02 3.71 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.806 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.7 Cg_endo -39.48 -31.74 0.4 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.477 2.118 . . . . 0.0 112.188 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 -62.19 -48.69 78.93 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.438 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.409 ' N ' ' O ' ' A' ' 9' ' ' ILE . 8.4 m-30 -59.32 -19.58 47.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.619 179.078 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -53.08 -73.64 0.38 Allowed Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.644 -179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -68.1 -24.06 39.14 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.475 2.117 . . . . 0.0 112.381 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.68 50.99 1.9 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.131 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.288 -0.863 . . . . 0.0 111.12 -179.975 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 60.43 32.59 20.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.847 0.356 . . . . 0.0 111.082 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.49 -57.35 4.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.5 HG23 ' H ' ' A' ' 6' ' ' LEU . 7.1 tp -113.63 -17.13 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.236 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.635 ' O ' HD23 ' A' ' 6' ' ' LEU . . . 118.24 -17.99 11.33 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.362 -179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.635 HD23 ' O ' ' A' ' 5' ' ' GLY . 89.0 mt -144.74 24.01 1.54 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.704 0.288 . . . . 0.0 110.957 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -107.37 33.36 4.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.993 0.425 . . . . 0.0 111.067 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.405 ' O ' ' CG ' ' A' ' 11' ' ' TYR . 42.0 p-90 -109.8 -37.6 5.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.399 179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.749 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -53.43 -42.97 94.45 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 115.54 -0.755 . . . . 0.0 112.276 -179.113 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.717 ' HD3' HG23 ' A' ' 9' ' ' ILE . 1.0 OUTLIER -42.47 -28.13 0.93 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.233 1.955 . . . . 0.0 111.721 179.451 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.405 ' CG ' ' O ' ' A' ' 8' ' ' TRP . 8.7 m-30 -52.9 -36.73 59.77 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.838 179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -70.31 -37.03 74.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.901 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 56.93 103.0 0.01 OUTLIER Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.563 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.67 126.23 13.76 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.516 2.144 . . . . 0.0 112.279 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -102.16 102.48 12.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.024 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.229 -0.891 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.199 0 N-CA-C 112.576 -0.209 . . . . 0.0 112.576 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.46 45.82 0.56 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.906 0.384 . . . . 0.0 111.016 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.76 -14.61 13.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.41 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.0 tp -119.74 -36.44 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.001 0.429 . . . . 0.0 111.099 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.782 ' C ' HD12 ' A' ' 6' ' ' LEU . . . -60.3 -22.17 58.09 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.229 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.782 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.7 mp -126.11 31.04 5.51 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.791 0.329 . . . . 0.0 110.766 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.42 14.95 30.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.591 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 35.2 p-90 -111.3 -39.35 4.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.155 0.502 . . . . 0.0 110.61 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.76 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -53.62 -42.72 93.67 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.444 -179.18 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.707 ' HD3' HG23 ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.9 -28.5 0.77 Allowed 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.26 1.973 . . . . 0.0 111.781 179.445 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -54.88 -39.18 68.43 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.89 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -79.5 -32.67 42.44 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.124 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 117.76 99.88 2.03 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.575 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 10' ' ' PRO . 24.1 Cg_exo -64.02 91.99 0.17 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.525 2.15 . . . . 0.0 112.19 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -146.32 74.32 1.36 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.116 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.114 179.997 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.134 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.74 35.98 4.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 111.12 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.65 -45.2 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.134 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.801 HG23 ' H ' ' A' ' 6' ' ' LEU . 11.0 tt -117.61 -14.6 9.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.186 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.808 ' C ' HD22 ' A' ' 6' ' ' LEU . . . 86.82 -3.22 87.17 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.129 -179.439 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.808 HD22 ' C ' ' A' ' 5' ' ' GLY . 2.3 mm? -130.53 27.31 5.01 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.849 0.357 . . . . 0.0 110.734 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -92.65 48.72 1.39 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.713 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 39.9 p-90 -118.81 -37.31 3.27 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.812 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.749 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.7 tt -58.09 -38.91 71.55 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.652 -179.258 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.749 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.0 OUTLIER -41.0 -29.82 0.52 Allowed 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.369 2.046 . . . . 0.0 111.763 179.428 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.6 m-30 -51.14 -45.42 61.63 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.475 178.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -83.02 -31.19 27.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.95 94.57 0.11 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.438 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.87 132.73 51.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.545 2.163 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.56 -176.9 0.66 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.207 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.083 0 CA-C-O 118.149 -0.929 . . . . 0.0 111.072 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.168 0 N-CA-C 112.61 -0.196 . . . . 0.0 112.61 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.21 -30.59 20.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.854 0.359 . . . . 0.0 111.175 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.55 -76.7 0.58 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.982 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.9 tt -110.55 -20.28 6.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.96 -15.77 4.01 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.702 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 90.9 mt 52.29 33.93 13.71 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.815 0.341 . . . . 0.0 111.112 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -98.95 30.63 3.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.013 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.401 ' C ' ' HD2' ' A' ' 10' ' ' PRO . 52.7 p-90 -124.95 -36.55 2.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.32 0.581 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.728 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 7.3 tt -56.33 -38.98 74.32 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.886 -179.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.728 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.2 Cg_endo -40.15 -29.1 0.31 Allowed 'Trans proline' 0 C--N 1.358 1.029 0 C-N-CA 122.331 2.021 . . . . 0.0 112.112 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.1 m-30 -51.92 -33.01 35.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.747 179.183 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.408 ' O ' ' HD3' ' A' ' 14' ' ' PRO . 4.4 m-85 -92.41 -34.29 14.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.275 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.32 104.86 0.53 Allowed Glycine 0 CA--C 1.518 0.246 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.673 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.408 ' HD3' ' O ' ' A' ' 12' ' ' PHE . 10.9 Cg_exo -71.55 143.94 43.7 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.809 2.34 . . . . 0.0 112.071 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 58.91 -175.01 0.09 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.159 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.238 -0.887 . . . . 0.0 111.119 -179.978 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.535 ' HA ' HD12 ' A' ' 6' ' ' LEU . . . -131.77 32.08 4.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.836 0.35 . . . . 0.0 111.108 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -139.8 -45.15 0.44 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.251 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.0 tp -116.35 -31.25 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.47 -11.51 82.55 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.473 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.535 HD12 ' HA ' ' A' ' 2' ' ' ALA . 86.6 mt -116.8 36.7 4.07 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.825 0.345 . . . . 0.0 110.842 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -117.69 37.49 3.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.148 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 37.1 p-90 -109.63 -37.99 5.54 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.22 0.534 . . . . 0.0 110.505 179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.752 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -55.38 -42.41 95.81 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.47 -179.185 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.709 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.2 Cg_endo -41.99 -28.36 0.79 Allowed 'Trans proline' 0 C--N 1.351 0.682 0 C-N-CA 122.336 2.024 . . . . 0.0 111.707 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -55.7 -39.31 70.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.903 179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -78.94 -33.3 45.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.201 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 125.99 102.1 1.29 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.481 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 10' ' ' PRO . 85.2 Cg_endo -83.77 -44.03 0.07 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.665 2.244 . . . . 0.0 112.414 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 61.85 166.13 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.101 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.159 -0.924 . . . . 0.0 111.069 179.913 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.55 -0.22 . . . . 0.0 112.55 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -100.97 24.31 9.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.686 0.279 . . . . 0.0 111.203 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -115.16 -29.24 6.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.187 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -76.05 -6.75 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.443 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.8 -5.57 14.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.248 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 6' ' ' LEU . 49.7 tp -95.25 49.13 1.19 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.183 0.516 . . . . 0.0 110.365 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -103.49 34.42 2.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.144 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.46 ' NE1' HD12 ' A' ' 6' ' ' LEU . 38.8 p-90 -125.01 -35.67 2.63 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.416 0.627 . . . . 0.0 110.146 179.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.763 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.3 tt -62.47 -36.89 30.85 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.082 -0.963 . . . . 0.0 112.894 -179.169 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.763 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.8 Cg_endo -39.91 -28.82 0.27 Allowed 'Trans proline' 0 C--N 1.357 0.993 0 C-N-CA 122.493 2.129 . . . . 0.0 112.237 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -59.19 -45.49 90.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.344 178.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -81.84 -34.29 30.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 143.49 107.19 0.58 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.524 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.21 88.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.548 2.165 . . . . 0.0 112.401 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 53.63 -167.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.246 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.001 179.931 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.127 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.62 42.67 16.87 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.848 0.356 . . . . 0.0 111.148 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 -35.56 30.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.11 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.8 pt -87.87 9.82 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.729 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.17 24.31 76.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.302 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 6' ' ' LEU . 48.1 tp -92.58 49.71 1.51 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.141 0.496 . . . . 0.0 110.538 -179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -120.73 42.59 2.98 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.63 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 35.9 p-90 -122.01 -34.5 3.34 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.442 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.753 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.1 tt -61.69 -38.13 47.47 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.784 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.753 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 2.6 Cg_endo -42.65 -26.27 0.61 Allowed 'Trans proline' 0 C--N 1.355 0.889 0 C-N-CA 122.331 2.021 . . . . 0.0 112.008 179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -58.44 -47.73 83.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.733 178.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -71.91 -22.4 61.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.396 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 155.17 107.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.562 -0.827 . . . . 0.0 112.7 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -76.55 148.91 29.98 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 122.507 2.138 . . . . 0.0 112.261 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . 59.5 -173.15 0.11 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.098 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.226 -0.892 . . . . 0.0 111.071 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.139 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.17 30.38 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.778 0.323 . . . . 0.0 111.092 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.92 -50.23 6.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.111 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 31.4 pt -82.73 2.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.571 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.21 15.99 70.52 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.297 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.566 HD11 HG21 ' A' ' 9' ' ' ILE . 53.7 tp -107.6 62.35 0.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.022 0.439 . . . . 0.0 110.569 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -127.95 34.97 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.987 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 33.2 p-90 -126.55 -35.71 2.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.345 0.593 . . . . 0.0 110.204 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.755 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.1 tt -62.17 -37.24 35.71 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.92 -179.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.755 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.5 Cg_endo -40.39 -28.31 0.3 Allowed 'Trans proline' 0 C--N 1.356 0.971 0 C-N-CA 122.406 2.071 . . . . 0.0 112.081 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -60.16 -47.23 86.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 178.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 8.2 m-30 -58.98 -30.75 68.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.88 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 142.37 -88.46 0.18 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.451 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.35 113.67 3.78 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.634 2.222 . . . . 0.0 112.361 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.668 ' HB2' ' HA ' ' A' ' 10' ' ' PRO . . . -112.82 69.55 0.69 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.117 -179.987 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.654 -0.178 . . . . 0.0 112.654 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.92 -41.97 3.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.879 0.371 . . . . 0.0 111.143 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -68.91 -56.2 8.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.017 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.536 ' O ' HG22 ' A' ' 4' ' ' ILE . 50.4 mm -119.01 -6.92 11.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.137 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 6' ' ' LEU . . . 86.52 -14.72 54.34 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.535 -0.84 . . . . 0.0 111.742 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.823 HD12 ' C ' ' A' ' 5' ' ' GLY . 3.8 mp -129.54 26.26 5.36 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.715 0.293 . . . . 0.0 110.675 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.25 39.74 1.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.135 0.493 . . . . 0.0 111.216 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 44.1 p-90 -124.21 -35.79 2.76 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.466 0.651 . . . . 0.0 110.284 179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.746 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.8 tt -58.98 -39.08 71.38 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.037 -0.983 . . . . 0.0 112.719 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.746 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 3.8 Cg_endo -43.55 -28.57 1.8 Allowed 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 122.173 1.915 . . . . 0.0 111.532 179.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.8 m-30 -49.23 -47.79 46.08 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.57 178.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -74.26 -29.63 61.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.831 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -117.63 65.3 0.36 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -71.79 132.99 21.06 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.602 2.202 . . . . 0.0 112.306 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.34 121.84 30.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.164 -0.922 . . . . 0.0 111.056 179.957 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.35 31.17 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.806 0.336 . . . . 0.0 111.075 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.85 -51.97 2.55 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.147 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.468 ' O ' HG22 ' A' ' 4' ' ' ILE . 50.1 mm -116.85 -11.71 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.219 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 77.84 0.09 73.66 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.965 -178.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 6' ' ' LEU . 44.3 tp -141.54 26.13 1.96 Allowed 'General case' 0 CA--C 1.528 0.115 0 CA-C-O 120.98 0.419 . . . . 0.0 110.643 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.23 47.44 1.08 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.072 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.519 ' NE1' HD12 ' A' ' 6' ' ' LEU . 34.9 p-90 -126.84 -35.25 2.31 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.345 0.593 . . . . 0.0 110.367 179.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.769 ' N ' ' HD2' ' A' ' 10' ' ' PRO . 6.2 tt -62.75 -37.21 32.16 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 115.091 -0.959 . . . . 0.0 112.948 -179.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.769 ' HD2' ' N ' ' A' ' 9' ' ' ILE . 1.1 Cg_endo -40.95 -27.54 0.32 Allowed 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 122.452 2.101 . . . . 0.0 111.995 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 8.3 m-85 -60.54 -46.91 88.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.524 178.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -77.15 -23.84 51.6 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.217 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.38 -107.24 0.01 OUTLIER Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.597 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.83 -179.78 1.46 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.556 2.171 . . . . 0.0 112.258 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -88.44 81.21 7.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.129 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.084 179.97 . . . . . . . . 0 0 . 1 stop_ save_